An interventional study of Active telemonitoring using real-time data from digital inhalers. and Standard in Pediatric Asthma, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 6 under way, none of them phase 3. Asthma · Assistance Publique - Hôpitaux de Paris.
Among the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 31st registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →5 of the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6+
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 4 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 90 across the 13 interventional studies, 113 across the 18 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Asthma by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04763447Assistance Publique - Hôpitaux de ParisShort Treatment with Omalizumab for Severe Asthma | 2027-05-20 |
| NCT06902766Assistance Publique - Hôpitaux de ParisTowards Digital Management of Paediatric Asthma | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study aims to explore whether a digital approach to managing childhood asthma using connected inhalers and video consultations triggered by alerts from these devices - could work as well as standard in-person care. The connected inhalers track when children use their daily prevention medication and their rescue medication for asthma symptoms. If a child misses several days of prevention medication or uses their rescue inhaler frequently, their doctor receives an alert and can schedule a video consultation to adjust their treatment. Fifty children aged 4-12 years with asthma will participate for 8 months, with half using this digital system and half receiving usual care. The study will measure whether this new approach is practical and acceptable to families and doctors, and will look at its effects on asthma control, quality of life, and healthcare use. The results will help design a larger study to fully test if this digital approach could improve asthma care for children.
Asthma is the most common chronic illness in children. In France, two-thirds of children have uncontrolled asthma, meaning they experience symptoms and occasional asthma attacks.
The digital revolution has enabled the development of connected devices, particularly smart inhalers, which collect objective information for assessing asthma from patients' homes. The Covid-19 pandemic has further accelerated the adoption of telemedicine. These new approaches represent a significant shift in paediatric asthma management, offering opportunities for more effective treatment methods.
As a precursor to a larger investigation, this pilot study hypothesises that digital asthma management using proactive remote care through telemedicine consultations triggered by connected device alerts may improve childhood asthma control compared to current management approaches.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Whose parents or legal guardian(s):
Non-inclusion Criteria:
Exclusion Criteria:
- Patient who did not use the system within 15 days of the inclusion visit
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active telemonitoring using real-time data from digital inhalers
Device: Active telemonitoring using real-time data from digital inhalers.
The patients are monitored as usual according to the standard care protocol. Patients will receive 2 digital inhalers, but only to record their treatment use.
Other: Standard
Telemonitoring system relying on the use of 2 digital inhalers FindAir ONE for pMDI,one for the controller the other for the reliever treatment. Active telemonitoring using real-time data from digital inhalers Investigators will be alerted by email if a child: * fails to take his or her controller treatment for 4 continuous days and/or * uses \> 4 doses of reliever treatment over 24 hours * uses \< 12 doses of reliever treatment over 3 months (indication to decrease the controller treatment). For alert (2), a teleconsultation will be scheduled within 2 working days to assess and adapt treatment as needed. Emergency treatment may be adjusted for approximately one week. Alerts within the following 7 days will be considered part of the same clinical episode. For alerts (1) and (3), a teleconsultation will be scheduled within 7 working days to assess and adapt management as needed.Spirometry and pulse oximetry if needed.
Standardized care + passive recording of asthma treatment use (controller and reliever treatments) using digital inhalers
Change in asthma severity measured by the Composite Asthma Severity Index (CASI)
The CASI is a validated composite score that evaluates asthma severity by incorporating measures of asthma symptoms, exacerbations, lung function, and treatment level. The change in CASI score will be compared between groups, calculated as the difference between the final score (at 8 months) and the baseline score. Lower scores indicate less severe asthma. The CASI ranges from 0 to 17, with higher scores meaning a higher severity (worse outcome).
Time frame: At the inclusion visit (baseline) and 8 months (+/- 1 month) (end of study) in each group
Asthma control
Evolution in the overall Childhood Asthma Control Test (c-ACT) score. The c-ACT (Childhood Asthma Control Test) will be used to evaluate the evolution of asthma control. The c-ACT ranges from 0 min to 27 max, with higher scores meaning better asthma control (better outcome).
Time frame: At the inclusion visit (baseline) and 8 months (+/- 1 month) (end of study) in each group
Severe exacerbations requiring oral steroids
Severe exacerbations (defined as an exacerbation requiring oral corticosteroid therapy): number of severe exacerbations per patient and percentage of patients with at least one severe exacerbation
Time frame: During the eight-month follow up period in each group
Severe exacerbations requiring emergency department visit and/or hospital admission.
Severe exacerbations requiring emergency department visits and/or hospitali admission: number per patient and percentage of patients with at least one
Time frame: During the eight-month follow up period in each group
Children's lung function
Evolution of lung function assessed by the predicted percentage of the forced expiratory volume in one second (FEV1) in children aged 7 to 12 years
Time frame: At the inclusion visit (baseline) and 8 months (+/- 1 month) (end study) in each group
Quality of life questionnaire
Children (aged 7 -12 years) were assessed by the mini Pediatric Asthma Quality of Life Questionnaire (mPAQLQ). Their parents were assessed by the Pediatric Asthma Caregivers' Quality of Life.
Time frame: At the inclusion visit (baseline) and 8 months (+/- 1 month) (end of study) in each group
Adherence
The adherence of patients to their maintenance treatment, automatically recorded via digital inhalers, defined as the number of doses taken divided by the number of doses prescribed x 100: average percentage of adherence
Time frame: During the eight-month follow up period in each group
Reliever treatment
Use of reliever treatment (salbutamol) is automatically recorded via digital inhalers: average number of uses per each patient
Time frame: During the eight-month follow up period in each group
Number of teleconsultations/consultations
Average number of consultations/teleconsultations per patient, scheduled and unscheduled, and their average cumulative duration per patient
Time frame: During the eight-month follow up period in each group
Children participation
The child's speaking time compared to the total speaking time (child + parent + doctor), expressed as a percentage was determined from video recordings. The number of the child's speech turns compared to the total number of speech turns (child + parent + doctor), expressed as a percentage. The number of complete thoughts, or "utterances", of the child compared to the total number of complete thoughts, expressed as a percentage. The child's non-verbal communication, analyzed by a module of the Roter Interactive Assessment System
Time frame: During the eight-month follow up period in each group
Absenteeism
Number of days of asthma-related absenteeism (from school for children and work for parents), per patient
Time frame: During the eight-month follow up period in each group
Satisfaction of parents
Assessed by the proportion of parents in the experimental group responding on a custom questionnaire that they wish to continue the digital management experience and the reason for their choice
Time frame: After 8 months (+/- 1 month) (end of study)
Satisfaction of doctors
Assessed by the proportion of doctors in the experimental group responding on a custom questionnaire that they wish to continue the digital management experience and the reason for their choice
Time frame: After 8 months (+/- 1 month) (end of study)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.
Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 20 months is below that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jan 2027 → Jul 2027 and completion Jan 2027 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →